(888) 552-6760 SCHEDULE A CONSULTATION
Clinical-Trials

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

44 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is an open-label, multicenter, global phase II basket study of entrectinib (RXDX-101) for the treatment of participants with solid tumors that harbor an NTRK1/2/3, ROS1 or ALK gene fusion. Participants will be assigned to different baskets according to tumor type and gene fusion.

This study will evaluate the safety (side effects) and antitumor activity of study drug in men and women with advanced cancer, based on certain types of DNA defect or damage.

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is an open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study will evaluate the safety and tolerability profile of GSK2857916 when administered in combination with approved regimens of either lenalidomide plus dexamethasone [Len/Dex (Arm A)] or bortezomib plus dexamethasone [Bor/Dex (Arm B)] in participants with RRMM, i.e., those who have relapsed or who are refractory to at least one line of approved therapy.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study is a phase 1, open-label, multi-center dose escalation and dose expansion study in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with recurrent platinum-resistant ovarian cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The proposed clinical trial is designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine as a first-line treatment for naïve subjects with stage IV metastatic pancreatic carcinoma. The first part of study will focus on the treatment of pancreatic cancer with 200 mg three times a day and 300 mg three times a day, clinical treatment duration of four weeks, to determine the maximum dose of antroquinonol in combination with a standard dose regimen of nab-paclitaxel and gemcitabine. The extended phase II part of the study will focus on the efficacy of antroquinonol with standard treatment.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.